paper
author
question
whether
develop
vaccin
cryptosporidiosi
could
taken
consider
necess
feasibl
vaccin
human
veterinari
applic
discuss
development
stage
within
life
cycl
parasit
might
act
possibl
target
vaccin
develop
summaris
well
target
antigen
oer
molecular
biolog
immunolog
studi
vaccin
trial
cryptosporidiosi
carri
far
includ
activ
passiv
immunis
approach
also
overview
seem
respect
cryptosporidium
vaccin
two
target
group
consid
children
develop
world
neonat
rumin
antigen
repres
possibl
candid
subunit
vaccin
base
function
locat
andor
immun
respons
evok
activ
vaccin
newborn
calv
lamb
goat
kid
face
number
import
limit
passiv
immunis
approach
dam
immunis
protect
progeni
colostr
transfer
proven
valuabl
altern
final
number
point
action
near
futur
put
forward
past
two
decad
increas
recognit
cryptosporidiosi
harm
dicult
control
infecti
diseas
human
anim
parallel
number
paper
subject
given
emerg
medic
econom
impact
diseas
rise
knowledg
biolog
cryptosporidium
spp
interact
host
one
might
question
whether
develop
vaccin
cryptosporidiosi
intern
journal
parasitolog
australian
societi
parasitolog
inc
publish
elsevi
scienc
ltd
right
reserv
pii
x
pursu
member
work
group
iii
cryptosporidiosi
cyclosporosi
action
commiss
european
union
give
overview
knowledg
relev
respect
question
commerci
aspect
cryptosporidium
vaccin
mention
realis
success
commercialis
novel
research
convert
licens
vaccin
confront
obstacl
addit
work
question
ask
consid
develop
vaccin
human
cryptosporidiosi
vaccin
necessari
word
frequenc
sever
human
cryptosporidiosi
justifi
develop
vaccin
popul
vaccin
strategi
second
question
whether
acquisit
vaccin
protect
cryptosporidium
parvum
feasibl
answer
question
need
take
account
frequenc
sever
human
cryptosporidiosi
seroepidemiolog
studi
indic
transmiss
c
parvum
human
popul
frequent
especi
develop
world
anticryptosporidium
antibodi
detect
sera
popul
industrialis
countri
popul
develop
countri
term
clinic
symptom
analysi
data
studi
show
altogeth
c
parvum
detect
faec
diarrhoea
industrialis
countri
develop
countri
aid
review
studi
show
cryptosporidium
infect
diagnos
diarrhoea
develop
countri
develop
countri
although
incid
aid
cryptosporidiosi
decreas
dramat
sinc
use
tripleantiretrovir
therapi
costagliola
trend
incid
clinic
manifest
hiv
infect
antiretrovir
prescript
french
univers
hospit
confer
retrovirus
opportunist
infect
chicago
abstract
c
parvum
remain
threat
hiv
infect
patient
clinic
studi
show
c
parvum
infect
may
result
sever
symptom
classic
featur
cryptosporidiosi
aid
patient
may
experi
chronic
drugresist
choleralik
ill
dissemin
parasit
biliari
tract
bronchial
tree
addit
also
shown
young
children
cryptosporidium
infect
associ
increas
diarrhoea
morbid
malnutrit
may
result
declin
growth
given
import
diarrhoea
child
morbid
mortal
develop
countri
complic
like
major
impact
public
health
worldwid
basi
second
question
ask
consid
develop
vaccin
human
cryptosporidiosi
protect
clinic
cryptosporidiosi
achiev
vaccin
convinc
evid
immun
respons
involv
control
human
cryptosporidiosi
fact
cryptosporidium
infect
one
devast
opportunist
complic
aid
moreov
shown
aid
patient
clinic
outcom
cryptosporidiosi
relat
degre
immunosuppress
patient
count
mm
like
self
limitedinfect
also
report
patient
clear
cryptosporidium
infect
follow
discontinu
immunosuppress
treatment
howev
fact
immun
system
involv
control
establish
c
parvum
infect
necessarili
impli
immun
acquir
primari
contact
parasit
protect
futur
infect
two
experiment
studi
address
question
publish
one
show
volunt
rechalleng
oocyst
year
primari
exposur
c
parvum
experienc
clinic
ill
frequenc
primari
infect
howev
sever
symptom
intens
infect
lower
second
infect
moreov
recent
demonstr
upon
challeng
oocyst
infecti
dose
oocyst
volunt
preexist
antic
parvum
antibodi
increas
compar
infecti
dose
obtain
seroneg
volunt
final
epidemiolog
studi
perform
region
cryptosporidiosi
highli
endem
show
asymptomat
c
parvum
infect
possibl
suggest
repeat
exposur
parasit
may
result
protect
immun
base
inform
develop
vaccin
cryptosporidiosi
consid
public
health
prioriti
human
medicin
answer
question
dier
accord
geograph
econom
paramet
industrialis
countri
control
clinic
cryptosporidiosi
probabl
reli
develop
new
antivir
chemotherapeut
regimen
hiv
infect
patient
improv
procedur
water
vaccin
hand
vaccin
approach
could
eventu
consid
countri
poor
sanitari
condit
almost
imposs
control
transmiss
parasit
inde
countri
impact
cryptosporidiosi
child
develop
appal
cost
antivir
chemotherapi
aid
patient
confer
cryptosporidiosi
public
health
import
respect
put
cryptosporidium
vaccin
part
multicompon
vaccin
target
c
parvum
well
gastrointestin
pathogen
public
health
relev
howev
addit
data
still
need
one
accur
answer
question
need
human
vaccin
new
clinicoepidemiolog
analys
perform
sever
distinct
geograph
area
impact
cryptosporidiosi
nutrit
statu
develop
young
children
consequ
combin
antivir
chemotherapi
aid
cryptosporidiosi
also
evalu
hindsight
final
larg
popul
genet
pathogen
studi
necessari
inde
c
parvum
isol
shown
classifi
two
genotyp
one
human
human
livestock
current
data
suggest
genotyp
distinct
virul
moreov
widmer
et
al
recent
describ
higher
degre
polymorph
c
parvum
isol
show
recombin
two
main
genotyp
may
occur
case
would
vaccin
human
cryptosporidiosi
appear
public
health
prioriti
futur
year
decis
obvious
need
addit
inform
studi
aim
determin
genet
structur
c
parvum
characteris
pathogen
dierent
genotyp
would
preliminari
requir
ensur
choic
appropri
target
two
question
necess
feasibl
address
consid
develop
cryptosporidium
vaccin
veterinari
applic
cryptosporidium
infect
great
varieti
farm
anim
parasit
recognis
econom
import
calv
c
parvum
consid
commonli
detect
enteropathogen
agent
review
infect
preval
age
day
main
present
sign
diseas
ie
diarrhoea
associ
profus
shed
infect
oocyst
relat
ageclass
multipl
suckler
beef
herd
dairi
farm
multiplecow
matern
facil
fatten
unit
higher
risk
mani
drug
test
far
limit
number
eectiv
cryptosporidium
even
less
commerci
avail
also
lamb
goat
kid
c
parvum
frequent
aetiolog
agent
involv
outbreak
diarrhoea
outbreak
lamb
goat
kid
absenc
enteropathogen
mortal
higher
lamb
calv
morbid
reach
bird
cryptosporidiosi
often
manifest
respiratori
diseas
caus
cryptosporidium
baileyi
although
avian
cryptosporidiosi
long
consid
opportunist
diseas
recent
becam
evid
econom
underestim
review
piglet
cryptosporidiosi
preval
wean
anim
infect
mostli
asymptomat
rabbit
experiment
cryptosporidium
infect
caus
mortal
suckl
anim
outbreak
ageclass
rare
detect
wean
rabbit
infect
caus
subclin
enter
peeter
je
recent
advanc
intestin
patholog
rabbit
perspect
congress
world
rabbit
scienc
associ
budapest
hungari
pp
unless
immunosuppress
agent
concurr
present
given
inform
answer
question
arm
certain
host
speci
thu
ye
econom
loss
due
cryptosporidiosi
rumin
especi
small
rumin
justifi
develop
vaccin
avian
speci
cryptosporidiosi
clearli
emerg
health
problem
develop
vaccin
could
valuabl
although
receiv
highest
prioriti
howev
realis
necess
vaccin
would
exist
prevent
hygien
measur
would
explor
profoundli
anim
husbandri
vaccin
cryptosporidiosi
rumin
would
complet
gamut
alreadi
commercialis
vaccin
enteropathogen
agent
includ
rotaviru
coronaviru
bovin
viral
diarrhoea
viru
e
coli
salmonella
spp
review
applic
cryptosporidium
vaccin
would
least
environment
friendli
less
subject
develop
resist
drug
develop
en
mass
treatment
newborn
final
consid
introduct
anim
vaccin
c
parvum
might
reduc
environment
contamin
consequ
frequenc
andor
entiti
waterborn
cryptosporidiosi
outbreak
human
second
question
acquisit
vaccin
protect
c
parvum
feasibl
contrast
human
problem
relat
cryptosporidiosi
rumin
restrict
newborn
agerel
resist
observ
calv
lamb
older
anim
rais
isol
cryptosporidium
remain
suscept
infect
clinic
sign
much
less
sever
compar
observ
cryptosporidiuminfect
newborn
primari
exposur
c
parvum
rumin
becom
fulli
protect
challengeinfect
although
concept
primari
exposur
consid
caution
anim
cryptosporidiosi
inde
anim
start
excret
oocyst
contamin
environ
becom
continu
expos
parasit
consequ
shed
oocyst
protect
immun
acquir
great
rang
clinic
ill
observ
among
anim
expos
similar
condit
receiv
singl
experiment
infect
dose
oocyst
day
age
calv
excret
oocyst
day
diarrhoea
vari
greatli
durat
day
sever
calf
calf
variabl
probabl
due
dierent
immunocompet
statu
individu
calv
shortli
birth
like
distinct
genet
makeup
hamper
applic
potenti
vaccin
calv
lamb
goat
kid
show
peculiar
around
parturit
certainli
vaccin
approach
placenta
rumin
syndesmochori
transplacent
passag
immunoglobulin
molecul
total
prevent
neonat
born
virtual
agammaglobulinaem
newborn
anim
receiv
larg
amount
passiv
igg
colostrum
via
intestin
absorpt
h
life
review
passiv
immunis
neonat
rumin
via
colostr
antibodi
eectiv
exploit
mani
vaccin
protocol
frequent
elev
antibodi
level
hyperimmun
colostrum
achiev
preparturi
vaccin
dam
toxoid
kill
bacteria
inactiv
virus
review
also
colostr
lymphoid
cell
cross
gastrointestin
barrier
seem
immun
respons
newborn
rumin
colostrum
contain
varieti
solubl
immunomodulatori
factor
review
could
absorb
circul
suckl
infant
immedi
birth
thu
function
immun
result
ingest
colostrum
mediat
matern
antibodi
predominantli
igg
alon
probabl
also
transfer
matern
lymphoid
cell
immunoregulatori
cytokin
unlik
passiv
immunis
rumin
colostr
transfer
vaccin
dam
mention
activ
vaccin
newborn
face
import
limit
activ
vaccin
young
anim
detect
serum
concentr
matern
antibodi
success
stimul
immun
matern
antibodi
block
eect
vaccin
antigen
obstacl
avoid
administ
colostrum
free
antibodi
direct
vaccin
antigen
although
admit
dicult
perform
probabl
import
experiment
approach
ii
care
select
antigen
recognis
matern
antibodi
refer
develop
tcell
vaccin
theileria
babesia
antigen
select
potenti
stimul
tcell
recognit
antibodi
iii
administ
vaccin
mucos
site
less
subject
neutralis
matern
antibodi
circul
iv
nucleic
acid
vaccin
moreov
immun
respons
provok
activ
vaccin
neonat
must
necessarili
primari
respons
rel
long
period
latenc
low
concentr
antibodi
produc
sinc
anim
expos
cryptosporidium
day
birth
question
whether
activ
vaccin
capabl
mediat
immun
protect
earli
infect
howev
cryptosporidium
vaccin
would
design
evok
steril
protect
rather
reduc
product
loss
caus
clinic
ill
sever
eectiv
vaccin
base
inocul
live
parasit
develop
protozoan
infect
review
vaccin
eimeria
spp
use
line
parasit
repeatedli
select
precoci
develop
chicken
rabbit
knowledg
two
report
approach
respect
cryptosporidium
spp
though
without
success
oocyst
obtain
passag
c
baileyi
chicken
embryo
still
caus
clinic
respiratori
diseas
c
parvum
oocyst
obtain
day
patenc
fed
calv
success
gener
also
miss
select
precoci
develop
moreov
one
might
question
whether
accept
appli
live
attenu
parasit
strain
zoonot
agent
c
parvum
inde
preced
veterinari
medicin
instanc
commercialis
live
attenu
vaccin
toxoplasma
gondii
brucella
aborti
although
latter
potenti
risk
human
demonstr
basic
three
dierent
group
potenti
target
within
monoxen
cycl
parasit
oocyst
extracellular
stage
intracellular
stage
oocyst
transmiss
form
parasit
produc
sexual
reproduct
shed
environ
faec
consist
resist
oocyst
wall
protect
invas
form
sporozoit
extern
suitabl
oocyst
target
vaccin
develop
question
point
oocyst
wall
appar
chemic
physic
inert
structur
thu
unlik
repres
good
target
immunolog
intervent
howev
exclud
attack
oocyst
appropri
immun
eector
mechan
could
contrast
onset
infect
inhibit
excyst
bind
put
host
ligand
unknown
oocyst
wall
compon
furthermor
shown
oocyst
wall
share
immunogen
epitop
parasit
stage
suggest
antibodi
rais
crossreact
determin
oocyst
wall
may
play
protect
role
later
life
cycl
sporozoit
merozoit
invas
stage
parasit
sporozoit
releas
oocyst
excyst
merozoit
set
free
infect
host
cell
asexu
develop
parasit
microgamet
third
form
extracellular
stage
cryptosporidium
fertilis
macrogamont
lead
zygot
format
extracellular
stage
vulner
condit
within
host
intestin
inactiv
physic
chemic
infect
host
cell
quickli
short
life
span
tzipori
grith
argu
due
limit
surviv
time
gut
lumen
chemotherapeut
immunotherapeut
agent
direct
extracellular
form
c
parvum
unlik
highli
eectiv
regard
neutralis
antibodi
result
vaccin
eectiv
concentr
present
time
possibl
site
invas
inde
escap
singl
parasit
vaccin
immun
like
result
complet
whole
life
cycl
develop
clinic
diseas
problem
similar
preerythrocyt
vaccin
malaria
give
none
protect
obvious
need
eectiv
vaccin
major
diculti
immunis
strategi
nevertheless
variou
report
eect
neutralis
immunoglobulin
includ
mab
ig
hyperimmun
bovin
colostrum
hen
egg
demonstr
antigen
localis
surfac
zoit
stage
especi
sporozoit
review
moreov
zoit
stage
microgamet
occur
freeli
intestin
lumen
surround
host
microvilli
membran
like
phagocytos
digest
peyer
patch
mcell
thu
compon
like
present
tcell
mhc
class
iirestrict
way
tcell
respond
mhc
class
iirestrict
antigen
present
shown
play
pivot
role
clearanc
infect
discuss
section
detail
intracellular
stage
c
parvum
includ
trophozoit
two
type
meront
microgamont
macrogamont
show
uniqu
locat
describ
intracellular
extracytoplasm
render
well
protect
gut
lumen
two
membran
layer
includ
host
microvilli
membran
parasitophor
vacuol
membran
addit
outer
inner
parasit
pellicl
membran
intracellular
stage
separ
host
cell
cytoplasm
electron
dens
band
feeder
organel
membran
intracellular
form
parasit
may
repres
major
target
cellular
host
respons
histolog
studi
reveal
cellular
plasma
cell
neutrophil
tcell
site
infect
although
eector
mechan
need
enterocyt
potenti
present
antigen
pathogen
harbour
intracellularli
mhc
class
irestrict
way
evok
tcelldepend
cytotox
howev
evid
would
occur
c
parvum
infect
advent
extrem
fast
develop
molecular
biolog
great
impact
mani
biomed
research
includ
vaccinolog
advantag
oer
molecular
biolog
vaccin
develop
parasit
manifold
includ
theoret
possibl
access
entir
antigen
repertoir
organ
gene
overcom
limit
constraint
biochem
approach
hamper
rel
abund
access
given
parasit
molecul
ii
avail
prokaryot
eukaryot
express
system
product
reason
cost
larg
amount
recombin
antigen
devoid
toxic
contamin
iii
direct
use
gene
dna
vaccin
iv
possibl
engin
clone
gene
enhanc
immunogen
encod
vaccin
target
success
molecular
approach
develop
vaccin
requir
adequ
knowledg
molecular
biolog
organ
studi
proper
molecular
biolog
research
c
parvum
start
rel
late
earli
decad
number
dna
sequenc
deposit
databas
rose
current
dramat
increas
gener
grow
interest
apicomplexan
parasit
mainli
due
recent
start
genom
project
base
partial
sequenc
randomli
select
genom
dna
gst
st
project
cdna
est
project
clone
inform
world
wide
web
http
mercuryebiacukparasitescparvhtml
furthermor
happi
map
c
parvum
genom
recent
complet
oer
possibl
better
understand
overal
organis
parasit
genom
approach
repres
eectiv
way
gene
discoveri
c
parvum
howev
despit
consider
amount
novel
genet
inform
provid
random
strategi
number
c
parvum
genesprotein
far
characteris
extens
therefor
evalu
potenti
vaccin
target
limit
tabl
gene
clone
dierent
laboratori
adopt
variou
molecular
approach
includ
cytoskelet
compon
ii
nuclear
protein
iii
enzym
iv
factor
involv
rna
translat
v
heat
shock
protein
vi
oocyst
wall
constitu
well
vii
surfac
micronem
antigen
sporozoit
protein
belong
latter
class
seem
repres
present
state
knowledg
best
candid
develop
vaccin
cryptosporidiosi
statement
take
account
peculiar
aa
sequenc
oppos
clone
c
parvum
molecul
share
high
homolog
host
counterpart
ii
presenc
extracellular
parasit
stage
impli
higher
suscept
humor
immun
respons
iii
put
involv
key
function
parasit
establish
within
host
six
c
parvum
sporozoit
protein
clone
far
five
localis
either
sporozoit
surfac
micronem
thrombospondinrel
adhes
protein
precis
locat
sporozoit
cysteinerich
protein
scrp
spano
et
al
unpublish
present
studi
low
mol
wt
polypeptid
aa
respect
whose
gene
clone
screen
c
parvum
express
librari
mab
polyclon
antibodi
rais
oocystsporozoit
lysat
despit
lack
put
leader
peptid
extracellular
target
transmembran
gpianchor
signal
aa
sequenc
analys
suggest
three
protein
locat
membran
sporozoit
case
membran
merozoit
subcellular
fraction
show
found
micronem
c
parvum
sporozoit
petri
et
al
unpublish
evid
corrobor
observ
shed
surfac
sporozoit
glide
motil
subcellular
localis
would
point
antigen
possibl
vaccin
candid
surfac
antigen
c
parvum
sporozoit
clone
date
howev
previou
electrophoret
analysi
radioiodin
sporozoit
show
plasmamembran
parasit
stage
display
dierent
protein
antigen
complex
could
exploit
futur
search
novel
vaccin
target
recent
host
cell
invas
zoit
apicomplexa
shed
new
light
function
role
possibl
immunolog
potenti
parasit
protein
locat
micronem
apic
organel
known
play
crucial
role
earli
step
invas
content
releas
interfac
zoit
host
cell
lead
interact
micronem
protein
surfac
receptor
host
due
involv
process
pivot
import
establish
infect
transitori
display
parasit
surfac
upon
interact
host
cell
micronem
protein
intens
studi
vaccin
candid
especi
plasmodium
falciparum
two
c
parvum
protein
show
distinct
molecular
architectur
share
localis
micronem
clone
far
highli
glycosyl
molecul
polypep
tidic
backbon
approxim
kda
possess
put
transmembran
region
tmr
two
mucinlik
domain
distinct
cysteineand
threoninerich
motif
well
short
aa
repeat
protein
localis
micronem
sporozoit
merozoit
immunoem
also
found
expos
sporozoit
surfac
shed
glide
motil
furthermor
antibodi
direct
dierent
domain
shown
inhibit
sporozoit
invas
vitro
claim
direct
role
molecul
interact
second
micronem
protein
recent
clone
adopt
pcrbase
approach
c
parvum
dna
sequenc
encod
type
repeat
human
protein
thrombospondin
tsp
tsp
type
repeat
adhes
aa
motif
confer
protein
abil
bind
sulphat
sugar
clone
molecul
possess
tsp
type
repeat
describ
among
protozoan
exclus
apicomplexan
parasit
genera
plasmodium
toxoplasma
eimeria
aa
long
polypeptid
show
leader
peptid
ii
six
tsp
type
repeat
iii
tm
iv
short
cytoplasm
domain
structur
featur
along
localis
micronem
sporozoit
share
tsprelat
protein
trap
plasmodium
spp
gondii
e
tenella
report
involv
homologu
substratedepend
locomot
sporozoit
well
host
cell
attach
invas
suggest
consid
promis
vaccin
candid
cryptosporidiosi
anoth
c
parvum
molecul
deserv
consider
point
view
vaccin
develop
mention
scrp
encod
singl
copi
gene
express
high
level
c
parvum
sporozoit
spano
et
al
unpublish
recent
clone
partial
cdna
predict
scrp
transmembran
protein
possess
one
epidermalgrowth
factor
egf
like
domain
three
copi
tsp
type
repeat
spano
et
al
unpublish
overal
structur
featur
suggest
novel
member
tsp
famili
like
involv
interact
host
ligand
preliminari
studi
indic
wall
sporul
oocyst
contain
dierent
protein
despit
great
number
report
describ
reactiv
mab
oocyst
wall
constitu
one
c
parvum
oocyst
wall
protein
known
cryptosporidium
oocyst
wall
protein
cowp
one
c
parvum
protein
molecular
techniqu
screen
genom
express
librari
antiserum
rais
oocyst
homogen
abund
protein
kda
aa
long
typic
leader
peptid
consist
two
aa
domain
characteris
distinct
relat
cystinerich
repeat
immunoem
studi
show
cowp
accumul
wallform
bodi
matur
macrogamet
eventu
incorpor
inner
layer
oocyst
wall
immunolog
relev
cowp
natur
infect
well
understood
howev
presenc
protein
inner
oocyst
wall
seem
preclud
least
discourag
use
vaccin
target
paragraph
intend
review
immun
respons
cryptosporidium
infect
concentr
aspect
host
defenc
system
relev
vaccin
strategi
possibl
target
oer
studi
immun
respons
acquir
cryptosporidium
infect
recent
review
dealt
immunolog
cryptosporidiosi
reader
interest
direct
articl
read
respect
vaccin
two
major
part
host
defenc
system
like
involv
gener
protect
immun
immunoglobulin
tcell
respons
role
immunoglobulin
elimin
parasit
controversi
evid
support
involv
antibodi
clearanc
infect
persist
cryptosporidiosi
congenit
hypogammaglobulinaem
individu
see
ii
good
tempor
associ
c
parvum
oocyst
excret
amount
iga
faec
calv
lamb
iii
protect
role
neutralis
antibodi
demonstr
abil
inhibit
invas
vivo
vitro
see
hand
observ
argu
import
antibodi
respons
oocyst
shed
pattern
dier
bcelldeplet
neonat
mice
bursectomis
chicken
control
ii
challeng
immun
calv
show
secondari
mucos
antibodi
respons
iii
aid
patient
persist
cryptosporidiosi
produc
c
parvum
serum
andor
mucos
igg
igm
iga
theoret
two
mechan
antibodi
action
distinguish
firstli
antibodi
act
lumin
block
parasit
interact
host
cell
prevent
attach
andor
invas
kind
action
could
greatli
facilit
eector
mechan
eg
complement
activationlysi
opsonophagocytosi
bind
fc
receptorsantibodydepend
cell
mediat
cytotox
thu
potenti
attack
extracellular
stage
also
noninvas
one
outlin
secondli
crabb
suggest
cryptosporidium
antibodi
might
act
also
intracellularli
accord
novel
mechan
recent
describ
rotaviru
infect
secretori
iga
inhibit
intracellular
viru
assembl
transcytosi
infect
epitheli
cell
mechan
secretori
iga
may
repres
promis
ig
isotyp
capac
transcytosi
dimer
form
secretori
compon
reason
stabl
environ
intestin
lumen
favennec
et
al
shown
aid
patient
cryptosporidiosi
serum
faecal
iga
respons
mainli
subclass
primarili
gener
polypeptid
glycoprotein
wherea
subclass
respond
polysaccharid
antigen
underrepres
wherea
quantit
level
igg
igm
iga
determin
mani
studi
qualiti
antibodi
neutralisationsensit
antigen
epitop
poorli
studi
tradit
select
antigen
vaccin
purpos
base
domin
recognit
antibodi
immun
anim
comprehens
overview
antigen
recognis
immun
serummucos
antibodi
hyperimmun
serum
colostrum
mab
given
rigg
focu
well
studi
antigen
origin
screen
antibodi
immun
anim
kda
antigen
recognis
serum
faecal
antibodi
cryptosporidiuminfect
human
balbc
mice
rabbit
lamb
calv
piglet
goat
kid
antigen
comigr
sporozoit
surfac
antigen
design
see
section
mab
oral
administr
iga
mab
suckl
mice
provid
protect
infect
recent
studi
compar
antigen
two
dierent
recombin
form
one
produc
prokaryot
express
system
eukaryot
one
potent
immun
respons
obtain
use
eukaryot
form
possibl
due
posttransl
western
blot
analys
cryptosporidium
protein
use
serumfaec
antibodi
cryptosporidiuminfect
human
balbc
mice
rabbit
lamb
calv
piglet
goat
kid
hors
reveal
kda
immunoreact
polypeptid
antigen
comigr
protein
mab
localis
surfac
sporozoit
see
section
iga
mab
reactiv
shown
anticryptosporidi
activ
mice
undoubtedli
tlymphocyt
essenti
overcom
cryptosporidiosi
shown
fact
athym
nude
scid
mice
develop
chronic
infect
aid
patient
sever
drop
tcell
like
becom
serious
ill
infect
c
parvum
passiv
transfer
experi
shown
tcell
could
abrog
chronic
infect
nude
scid
mice
moreov
immunocompet
mice
infect
experiment
c
muri
deplet
tcell
mab
result
increas
infect
protect
immun
respons
cryptosporidi
infect
associ
product
interferongamma
ifng
tcell
typic
associ
helper
respons
natur
killer
cell
second
sourc
ifng
postul
scid
mice
show
initi
resist
due
action
innat
defenc
eector
system
despit
increas
knowledg
immunolog
host
interact
eector
mechan
lead
sterilis
immun
known
mcdonald
bancroft
discuss
ifng
may
increas
turnov
parasitis
epithelium
would
lead
acceler
shed
cell
villi
second
mode
action
involv
ifnginduc
kill
cryptosporidium
yet
demonstr
even
less
known
involv
cell
cytokin
parasit
kill
strategi
select
antigen
provok
tcell
respons
might
interest
altern
common
approach
screen
antigen
recognis
antibodi
use
crude
c
parvum
oocyst
extract
prolif
lymphocyt
respons
tcelldepend
ifng
product
describ
howev
approach
could
attribut
stimul
potenti
separ
antigen
fraction
fail
far
discov
new
tcell
antigen
seem
reason
believ
among
alreadi
known
c
parvum
antigen
certainli
must
tcell
stimul
potenti
demonstr
cowp
previou
section
list
number
protein
function
locat
immun
respons
evok
may
repres
candid
subunit
vaccin
howev
protect
abil
antigen
dna
vaccin
construct
vaccin
trial
compar
acquir
protect
challeng
infect
immunis
nonimmunis
anim
section
work
done
domain
respect
cryptosporidium
spp
overview
focu
trial
vaccin
administ
parenterallyor
order
elicit
protect
immun
respons
subsequ
cryptosporidium
infect
therapeut
use
antibodi
combat
cryptosporidiosi
mention
except
passiv
immunis
rumin
mother
immunis
protect
progeni
colostr
transfer
attempt
immunis
c
parvum
conduct
employ
oocyst
prepar
adopt
dnabas
approach
howev
far
vaccin
trial
remain
restrict
laboratori
domest
anim
condit
administr
colostrum
protect
calv
lamb
natur
acquir
infect
howev
calv
lamb
fed
colostrum
dam
receiv
im
inject
freezethaw
c
parvum
oocyst
sever
week
parturit
partial
protect
infect
socal
hyperimmun
colostrum
contain
high
titr
antibodi
jenkin
et
al
report
ewe
immunis
dna
technolog
plasmid
encod
protein
mount
igg
humor
respons
serum
colostrum
anim
respond
plasmid
either
im
inject
intramammari
immunis
ewe
high
dose
mg
plasmid
dna
sagodira
et
al
demonstr
given
nasal
rout
dose
low
mg
plasmid
dna
encod
surfac
protein
could
induc
humor
cellular
respons
mice
intestin
iga
detect
year
immunis
suggest
rout
vaccin
could
induc
longterm
respons
durabl
cellular
respons
also
found
mesenter
lymph
node
cell
still
prolifer
respons
c
parvum
extract
year
immunis
howev
none
two
latter
studi
design
determin
whether
acquir
immun
respons
provid
protect
cryptosporidium
infect
dam
progeni
knowledg
two
studi
follow
passiv
vaccin
approach
cryptosporidiosi
use
recombin
cryptosporidium
antigen
correspond
gene
perryman
et
al
immunis
late
gestat
cow
aniti
recombin
c
parvum
protein
contain
c
termin
aa
found
follow
challeng
infect
none
immun
colostrumtr
calv
develop
diarrhoea
anim
shed
fewer
oocyst
sagodira
et
al
show
vaccin
goat
gene
encod
protein
also
confer
high
level
protect
acut
cryptosporidiosi
newborn
kid
neonat
kid
born
vaccin
goat
shed
less
oocyst
control
kid
mean
durat
oocyst
excret
shorter
day
kid
born
vaccin
goat
kid
born
control
goat
day
monitor
daili
mean
weight
kid
born
vaccin
dam
sever
aect
parasit
develop
analysi
immun
respons
dam
follow
immunis
reveal
nasal
vaccin
induc
igg
iga
serum
colostrum
prolif
respons
spleen
cell
dierent
protect
unprotect
kid
precis
mechan
vaccin
reduc
diarrhoea
oocyst
develop
remain
unclear
addit
transfer
antibodi
immun
cell
colostrum
administr
author
question
whether
dna
immunis
could
sensitis
kid
utero
mount
cellmedi
humor
immun
respons
harp
go
develop
vaccin
oer
partial
protect
c
parvum
infect
calv
calv
receiv
oral
prepar
lyophilis
kill
c
parvum
oocyst
shortli
birth
mean
durat
diarrhoea
oocyst
shed
shorten
howev
test
larg
dairi
oper
heavi
endem
c
parvum
infect
vaccin
fail
provid
protect
hornok
et
al
report
attempt
immunis
avian
cryptosporidiosi
chicken
inject
twice
im
oocystsderiv
c
baileyi
protein
challeng
oral
c
baileyi
oocyst
total
oocyst
output
immunis
chicken
nonimmunis
control
dierenc
serum
antibodi
found
suggest
immun
mechan
involv
seem
two
target
group
develop
vaccin
cryptosporidiosi
would
children
develop
countri
newborn
rumin
instanc
vaccin
strategi
might
greatli
contribut
reduct
public
health
threat
control
prevent
measur
case
farm
anim
develop
vaccin
would
econom
loss
due
cryptosporidiosi
livestock
husbandri
especi
neonat
rumin
breed
limit
avail
eectiv
drug
acquisit
vaccin
immun
activ
immunis
presum
problemat
newborn
calv
lamb
kid
children
inde
sinc
cryptosporidium
infect
manifest
earli
life
farm
anim
remain
question
whether
activ
vaccin
capabl
mediat
immun
protect
time
addit
block
eect
circul
matern
antibodi
vaccin
antigen
impos
conscienti
select
antigen
administ
rout
vaccin
choos
activ
immunis
passiv
vaccin
dam
immunis
protect
progeni
colostr
transfer
provid
interest
altern
potenti
respect
cryptosporidium
vaccin
two
recent
studi
seem
dicult
predict
cryptosporidium
life
cycl
stage
repres
good
target
immunolog
intervent
fact
lack
knowledg
immun
eector
mechan
involv
parasit
stage
attack
clearanc
infect
tradit
immunolog
oer
number
possibl
target
antigen
vaccin
develop
base
domin
recognit
host
antibodi
protect
cryptosporidiosi
clearli
shown
depend
larg
tcell
howev
strategi
select
antigen
base
abil
elicit
tcell
respons
explor
insuci
far
studi
parasitederiv
antigen
molecular
approach
oer
variou
advantag
compar
biochem
one
number
c
parvum
sequenc
deposit
databas
increas
dramat
past
year
mainli
due
genom
project
howev
limit
number
c
parvum
gene
sucient
characteris
date
leav
much
genet
inform
larg
unexploit
answer
question
whether
vaccin
cryptosporidiosi
realiti
fantasi
conclud
possibl
develop
vaccin
livestock
mammal
appear
reason
realist
seem
need
vaccin
recent
data
calv
goat
shown
promis
result
moreov
consider
progress
recent
year
develop
mucos
adjuv
use
attenu
pathogen
vaccin
carrier
vaccin
cryptosporidiosi
would
progress
situat
may
dierent
human
medicin
data
still
necessari
determin
whether
eectiv
protect
c
parvum
achiev
vaccin
popul
like
strategi
case
lose
ground
research
vaccin
apicomplexa
includ
malaria
brought
us
two
decad
littl
success
overview
highlight
number
possibl
point
action
near
futur
clinicoepidemiolog
analysi
impact
cryptosporidiosi
nutrit
statu
develop
young
children
ii
studi
consequ
combin
antivir
chemotherapi
aid
cryptosporidiosi
iii
studi
immun
eector
mechan
involv
clearanc
infect
iv
cryptosporidium
tcell
antigen
v
understand
mechan
involv
passiv
immunis
neonat
rumin
colostr
transfer
vi
complet
characteris
new
target
oer
molecular
biolog
vii
protect
potenti
candid
vaccin
antigen
vaccin
trial
last
least
viii
studi
genet
structur
c
parvum
characteris
pathogen
dierent
genotyp
ensur
choic
appropri
target
